mk-4166
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 27, 2014 (NCT02132754)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFRSF18 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mk-4166
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03707457 | Phase 1 | Mar 22, 2019 | Bristol-Myers Squibb, Johns Hopkins University |
| NCT02132754 | Phase 1 | Jun 27, 2014 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1